Parkside Financial Bank & Trust Has $260,000 Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Parkside Financial Bank & Trust trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.5% during the fourth quarter, HoldingsChannel reports. The firm owned 783 shares of the company’s stock after selling 92 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Medpace were worth $260,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in MEDP. Centaurus Financial Inc. lifted its holdings in Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after acquiring an additional 29 shares in the last quarter. Schulhoff & Co. Inc. raised its position in shares of Medpace by 1.2% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock worth $874,000 after purchasing an additional 30 shares during the period. Lindenwold Advisors INC lifted its holdings in shares of Medpace by 1.6% during the 3rd quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock valued at $676,000 after purchasing an additional 32 shares in the last quarter. Stephens Inc. AR grew its position in shares of Medpace by 4.9% in the 4th quarter. Stephens Inc. AR now owns 752 shares of the company’s stock valued at $250,000 after purchasing an additional 35 shares during the period. Finally, M&T Bank Corp grew its position in shares of Medpace by 1.2% in the 3rd quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock valued at $1,068,000 after purchasing an additional 37 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Stock Up 0.4 %

NASDAQ:MEDP opened at $327.32 on Friday. The company has a market cap of $9.97 billion, a P/E ratio of 25.92, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77. The business has a 50 day moving average price of $342.66 and a two-hundred day moving average price of $345.44.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.